BNTC Projected Dividend Yield

Benitec Biopharma Inc ( NASDAQ : BNTC )

Benitec Biopharma is a clinical-stage biotechnology company focused on the development of genetic medicines. The platform, called DNA-directed RNA interference, combines RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Co. is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a genetic disorder. BB-301 is an adeno-associated viral vectors -based gene therapy designed to silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD).

20 YEAR PERFORMANCE RESULTS